#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biliary cancer metastatic Asthma Fungal infection PIK3CA-activated mutation Crigler-Najjar syndrome Hereditary motor and sensory neuropathy Complex regional pain syndrome Neonatal alloimmune thrombocytopenia Congenital myopathy Epstein-Barr virus infection Glycogen storage disease type II Encephalitis autoimmune Small cell lung cancer recurrent Piriformis syndrome Autoimmune demyelinating disease More trials…

    Learn about Rare Diseases

    IgA nephropathy Alexander disease – Basic Information Methylmalonic acidaemia – Treatment Castleman’s disease – Trials in Disease Primary immunodeficiency syndrome – Trials in Disease Langerhans’ cell histiocytosis – Life with Disease Hereditary optic atrophy – Diagnostics Stevens-Johnson syndrome – Basic Information Basal cell naevus syndrome – Basic Information Focal segmental glomerulosclerosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Utreglutide ZINC Ly3537982 Insulin Human (Rdna) Benzocaine Ruxolitinib Tuparstobart Nizaracianine Triflutate Ianalumab Ivacaftor Bi 706321 Mrna-4157 Pamidronate Disodium Carfilzomib Topiramate Pyruvic Acid Lorundrostat Befiradol (18F) Hepatitis B Surface Antigen Escitalopram Oxalate More therapies…

    Learn about Your Condition

    Systemic infection Triple positive breast cancer Laryngeal leukoplakia Infant sedation Persistent depressive disorder Diabetic retinopathy Affective disorder Vulval cancer recurrent Proteus syndrome Bronchitis Bladder cancer HER2 negative breast cancer Parkinson's disease Gastric cancer recurrent Dry eye More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Pathological Conditions, Signs and Symptoms

  • Study on the Effects of Rikkunshito on Functional Dyspepsia in Primary Care Patients

    Recruiting

    3 1
    Investigated Diseases:
    • Dyspepsia
    Investigated Drugs:
    • RIKKUNSHITO
    Belgium

  • Study on the Safety and Effectiveness of Vibegron for Children Aged 2 to 17 with Neurogenic Bladder Overactivity Using Clean Intermittent Catheterization

    Recruiting

    4 1 1
    Investigated Diseases:
    • Neurogenic bladder
    Investigated Drugs:
    • Vibegron
    Belgium Croatia Denmark Latvia Lithuania Norway +3

  • Study of belatacept, tacrolimus and ciclosporin in heart transplant patients at risk of kidney failure

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Complications of transplanted heart
    Investigated Drugs:
    • Belatacept
    • Ciclosporin
    • Tacrolimus
    France

  • Study on Fluid Removal Using Furosemide and Amiloride Hydrochloride in ICU Patients with Fluid Overload

    Recruiting

    3 1 1
    Investigated Diseases:
    • Critical illness
    Investigated Drugs:
    • Amiloride Hydrochloride
    • Furosemide
    • Furosemide Ph. Eur.
    Czechia Denmark Lithuania The Netherlands Sweden

  • Study on Personalized Treatment for Hormone Receptor Positive HER2 Negative Breast Cancer Using Capivasertib, Letrozole, and Bevacizumab for Eligible Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Capivasertib
    • Bevacizumab
    Norway

  • Study on Breast Cancer Treatment with Carboplatin for Patients in Neoadjuvant and Metastatic Stages

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Carboplatin
    Norway
Previous Page
1 … 4 5 6 7 8 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!